<DOC>
	<DOCNO>NCT00318123</DOCNO>
	<brief_summary>To evaluate therapeutic equivalence two arm treatment virological immunological response 48 week evaluate presence side effect follow-up period .</brief_summary>
	<brief_title>Study Evaluate Effectiveness ABC+3TC +EFV Once-Daily Regimens Versus KLT Twice-Daily Regimens Naive HIV Patients</brief_title>
	<detailed_description>The efficacy highly active antiretroviral treatment ( HAART ) demonstrate several clinical trial . Even , substantial proportion patient manage maintain correct viral suppression daily clinical practice . Adherence HAART treatment critical obtain lasting viral suppression . Thus , factor relate adherence high pill load take , complexity antiretroviral system , tolerability food restriction may effect viral replication . It demonstrate simpler regimen scant number tablet , without food restriction single take day safe , efficacious adherence improves . The combination abacavir 600 mg + lamivudine 300 mg QD single tablet novel dosage may help increase treatment adherence .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>1 . Age &gt; 18 year . 2 . HIV1 infect patient . 3 . Naive antiretroviral treatment . 4 . Candidate patient initiate antiretroviral treatment* . 5 . Subject able follow treatment period . 6 . Signature informed consent . 7 . Women may fertile age ( define least one year menopause undergoing surgical sterilisation technique ) , must undertake use two contraceptive method study , one least barrier method . 1 . Hepatic test &gt; 5 time normality . 2 . Pregnancy breastfeed . 3 . Treatment opportunistic infection neoplasms associate stable HIV last 6 week . 4 . Suspected documented resistance investigational drug . 5 . Known allergic hypersensitivity investigational drug similar drug . 6 . Subjects abusive consumption alcohol illegal drug . 7 . Patients participate another clinical trial . 8 . Terminal renal disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Simplification therapy</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
	<keyword>Virological effectiveness</keyword>
	<keyword>Immunological effectiveness</keyword>
	<keyword>HIV</keyword>
</DOC>